Abstract
Immunotherapy is one of the most promising disease-modifying alternatives for the treatment of Parkinson’s disease (PD), a neurodegenerative disorder that affects approximately 1.5 million people in the USA and 1 % of people over 60 years old. Both vaccination and passive immunization approaches with antibodies targeting alpha-synuclein (α-syn) have been extensively explored, especially since the discovery that this protein may propagate from cell to cell and be accessible to antibodies when embedded into the plasma membrane or in the extracellular space. Moreover, developing immunotherapies that discriminate abnormal conformations of α-syn using either monoclonal antibodies or single-chain variable fragments is a top priority in this field. Finally, research on intracellular antibodies (intrabodies) has shown promise for their use as novel therapeutic tools. In this chapter we provide an overview on the most relevant immunotherapeutic advances targeting α-syn in PD and related disorders, including the current Phase I clinical trials exploring this type of approach for PD patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Savica R, Grossardt BR, Bower JH et al. (2013) Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol70(7):859-866
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376
Dickson DW (2001) Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol 14(4):423–432
Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840
Takeda A, Hashimoto M, Mallory M et al (1998) Abnormal distribution of the non-Abeta component of Alzheimer’s disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest 78(9):1169–1177
McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872
Fortin DL, Nemani VM, Voglmaier SM et al (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25(47):10913–10921
George JM, Jin H, Woods WS et al (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15(2):361–372
Iwai A, Masliah E, Yoshimoto M et al (1995) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2):467–475
Uéda K, Fukushima H, Masliah E et al (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90(23):11282–11286
Masliah E, Iwai A, Mallory M et al (1996) Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer’s disease. Am J Pathol 148(1):201–210
Lashuel HA, Petre BM, Wall J et al (2002) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322(5):1089–1102
Tsigelny IF, Bar-On P, Sharikov Y et al (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 274(7):1862–1877
Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211
Reynolds AD, Banerjee R, Liu J et al (2007) Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol 82(5):1083–1094
Reynolds AD, Stone DK, Hutter JA et al (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 184(5):2261–2271
Orgogozo JM, Gilman S, Dartigues JF et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46–54
Masliah E, Rockenstein E, Adame A et al (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46(6):857–868
Mandler M, Valera E, Rockenstein E et al (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10(1):10
Mandler M, Valera E, Rockenstein E et al (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol 127(6):861–879
Schneeberger A, Mandler M, Mattner F et al (2010) AFFITOME® technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin 6(11):948–952
Valera E, Masliah E (2013) Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies. Pharmacol Ther 38(3):311–22
Masliah E, Rockenstein E, Mante M et al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6(4):e19338
Games D, Valera E, Spencer B et al (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci 34(28):9441–9454
Bae EJ, Lee HJ, Rockenstein E et al (2012) Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32(39):13454–13469
Bartels T, Ahlstrom LS, Leftin A et al (2010) The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys J 99(7):2116–2124
Tran HT, Chung CH, Iba M et al (2014) Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 7(6):2054–2065
Shahaduzzaman M, Nash K, Hudson C et al (2015) Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson’s disease. PLoS One 10(2), e0116841
Chames P, Van Regenmortel M, Weiss E et al (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157(2):220–233
Spencer B, Emadi S, Desplats P et al (2014) ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 22(10):1753–1767
Boddapati S, Levites Y, Suryadi V et al (2012) Bispecific tandem single chain antibody simultaneously inhibits beta-secretase and promotes alpha-secretase processing of AbetaPP. J Alzheimers Dis 28(4):961–969
Emadi S, Liu R, Yuan B et al (2004) Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43(10):2871–2878
Emadi S, Barkhordarian H, Wang MS et al (2007) Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 368(4):1132–1144
Bousset L, Pieri L, Ruiz-Arlandis G et al (2013) Structural and functional characterization of two alpha-synuclein strains. Nat Commun 4:2575
Zhou C, Emadi S, Sierks MR et al (2004) A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 10(6):1023–1031
Lynch SM, Zhou C, Messer A (2008) An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 377(1):136–147
Joshi SN, Butler DC, Messer A (2012) Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs 4(6)
Lo AS, Zhu Q, Marasco WA (2008) Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 181:343–373
Kvam E, Sierks MR, Shoemaker CB et al (2010) Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Eng Des Sel 23(6):489–498
Stefanovic AN, Stockl MT, Claessens MM et al (2014) alpha-Synuclein oligomers distinctively permeabilize complex model membranes. FEBS J 281(12):2838–2850
Congdon EE, Gu J, Sait HB et al (2013) Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 288(49):35452–35465
Murinello S, Mullins RF, Lotery AJ et al (2014) Fcgamma receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration. Invest Ophthalmol Vis Sci 55(1):247–258
Fuller JP, Stavenhagen JB, Teeling JL (2014) New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer’s disease. Front Neurosci 8:235
Kam TI, Song S, Gwon Y et al (2013) FcgammaRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer’s disease. J Clin Invest 123(7):2791–2802
Adolfsson O, Pihlgren M, Toni N et al (2012) An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 32(28):9677–9689
Näsström T, Gonçalves S, Sahlin C et al (2011) Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One 6(10):e27230
Lindstrom V, Fagerqvist T, Nordstrom E et al (2014) Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice. Neurobiol Dis 69:134–143
Patrias LM, Klaver AC, Coffey MP et al (2010) Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations. Clin Exp Immunol 161(3):527–535
Panza F, Logroscino G, Imbimbo BP et al (2014) Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? Curr Opin Psychiatry 27(2):128–137
Acknowledgements
Supported by National Institutes of Health (NIH) grants AG18440, AG022074, and NS044233.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Valera, E., Masliah, E. (2016). Immunotherapy Against α-Synuclein Pathology. In: Ingelsson, M., Lannfelt, L. (eds) Immunotherapy and Biomarkers in Neurodegenerative Disorders. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3560-4_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3560-4_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3558-1
Online ISBN: 978-1-4939-3560-4
eBook Packages: Springer Protocols